Genzyme, Impax Bury Hatchet Over Kidney Disease Drugs
Impax Laboratories Inc. on Tuesday settled patent infringement claims brought by Sanofi-Aventis SA subsidiary Genzyme Corp. over plans to make generic versions of two Genzyme kidney disease treatments, reaching a deal...To view the full article, register now.
Already a subscriber? Click here to view full article